This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

This study has been completed.
Information provided by:
RespireRx Identifier:
First received: June 26, 2002
Last updated: June 23, 2005
Last verified: February 2005
Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain. There is evidence CX516 enhances brain activity by specifically targeting remaining glutamate receptors in the affected portions of the brain. This study will test the safety and efficacy of CX516 in the symptomatic treatment of participants with mild cognitive impairment.

Condition Intervention Phase
Mild Cognitive Impairment Drug: CX516 (Ampalex®) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Efficacy And Safety Of CX516 (900 Mg t.i.d.) In Elderly Participants With Mild Cognitive Impairment. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 4-Week Study.

Resource links provided by NLM:

Further study details as provided by RespireRx:

Estimated Enrollment: 160
Study Start Date: April 2002
Estimated Study Completion Date: March 2003

Ages Eligible for Study:   55 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Clinical diagnosis of mild cognitive impairment
  • Good general health with no additional diseases that would interfere with the study.

Exclusion criteria

  • Any significant neurologic disease (other than suspected incipient Alzheimer's disease), such as Parkinson's disease, stroke, TIA's, multi-infarct dementia, Huntington's disease, head trauma, chronic CNS infection.
  • History of major depression or another major psychiatric disorder within the past 6 months.
  • History of schizophrenia, mania or recurrent psychotic episodes.
  • History of alcohol or DSM IV-diagnosed substance abuse or dependence disorder within the past year.
  • History of blackout, epilepsy or seizures, or an abnormal EEG as judged by the Investigator and considering the age of the participant.
  • Any clinically significant hepatic, renal, cardiovascular, pulmonary, gastrointestinal or hematological illness or unstable medical condition which could interfere with drug safety, or absorption, distribution, metabolism and excretion, or lead to difficulty complying with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00040443

United States, Arizona
Pivotal Research Centers
Peoria, Arizona, United States, 85381
United States, California
University of California Irvine
Irvine, California, United States, 92697
University of California at Los Angeles
Los Angeles, California, United States, 90095
University of California, San Diego
San Diego, California, United States, 92093
United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
United States, Florida
Sun Coast Gerontology Center, University of South Florida
Tampa, Florida, United States, 33617
United States, Iowa
Mercy Mayo Clinic
Des Moines, Iowa, United States, 50314
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
  More Information Identifier: NCT00040443     History of Changes
Other Study ID Numbers: CORX-CX516-012.1
Study First Received: June 26, 2002
Last Updated: June 23, 2005

Keywords provided by RespireRx:
Mild Cognitive Impairment
Memory Loss
Alzheimer's Disease
Brain Aging

Additional relevant MeSH terms:
Cognition Disorders
Mild Cognitive Impairment
Neurocognitive Disorders
Mental Disorders processed this record on August 21, 2017